Clinical Trials
13 trialsNCT07443137 2026-06-04
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
Stanford University
Phase 1 Not yet recruiting
NCT06014762 2026-05-07
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Poseida Therapeutics, Inc.
Phase 1 Active not recruiting
NCT02315612 2026-04-28
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT05020678 2026-04-20
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Nkarta, Inc.
Phase 1 Active not recruiting
NCT06544265 2026-04-14
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
Phase 1 Recruiting
NCT07121946 2026-02-10
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
LTZ Therapeutics, Inc.
Phase 1 Recruiting
NCT05950802 2025-12-08
ODIN
University Health Network, Toronto
Phase 1 Recruiting
NCT02996773 2025-11-10
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
Phase 1 Completed
NCT06712810 2025-10-10
Q702 for the Treatment of Patients With Hematologic Malignancies
Mayo Clinic
Phase 1 Recruiting
NCT05526313 2025-10-01
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1 Completed
NCT05621096 2025-09-25
Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
University of Nebraska
Phase 1 Active not recruiting
NCT05857969 2025-07-11
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Florida International University
Phase 1 Recruiting
NCT06830031 2025-06-13
C402
Shanghai Exuma Biotechnology Ltd.
Phase 1 Recruiting